Alain Leizorovicz.

It is standard practice to stop enoxaparin at the right time of discharge, even in sufferers with persistent risk factors for venous thromboembolism. Thus, the style of the trial favored better efficacy in the enoxaparin group than would be expected with common clinical care because patients in the enoxaparin group received prophylaxis for an extended duration than usual. The results of the ADOPT trial warrant comparison with two other contemporary trials evaluating extended thromboprophylaxis in medically ill patients.announced today the initiation of another research, in mice, to determine the optimal amount of treatment with AEOL 10150 when utilized as a countermeasure to Acute Radiation Syndrome in the lungs. This scholarly study, led by Zeljko Vujaskovic, M.D. Ph.D. Of Duke University, is made to build on the recently completed research that demonstrated the efficacy of AEOL 10150 as cure for damage to the lungs due to contact with radiation, and determine the most efficient length of delivery for treatment after publicity. AEOL 10150 has been proven to be safe and well tolerated in two phase 1 safety studies, and in animal research it has been established to be efficacious in safeguarding the lung area from radiation harm and raising survival at dosages in the number of 5 to 30 mg/kg given daily up to 24 hrs after irradiation and administered for as long as 10 weeks.